Lunai Bioworks (LNAI) Q4 2024 earnings summary

Executive summary

• Renovaro Inc. operates two segments: Renovaro Biosciences (pre-clinical cell/gene therapies for cancer and HIV) and Renovaro Cube (AI-driven cancer diagnostics). Focus has shifted to AI technology after acquiring GEDi Cube in February 2024.

• The company remains pre-revenue, has never generated sales, and continues to fund operations through equity and debt offerings.

• Management has streamlined operations and reduced costs, but substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and limited cash.

Financial highlights

• Net loss for the year ended June 30, 2024 was $80.7 million, up 103% from $39.7 million in 2023, driven by $42.6 million in intangible asset impairment, $11.6 million goodwill impairment, and higher G&A expenses.

• Operating expenses rose 112% year-over-year to $81.6 million, with G&A up 60% to $24.6 million and R&D down 35% to $2.7 million.

• Cash and cash equivalents at June 30, 2024 were $220,467, down from $1.87 million a year earlier; working capital deficit widened to $28.3 million.

• Accumulated deficit reached $324.7 million as of June 30, 2024.

• No revenue was generated in 2024 or prior years.

Outlook and guidance

• The company does not expect to generate revenue in the near term and anticipates continued operating losses as it invests in R&D and commercialization.

• Management plans to seek additional funding through equity or debt, but there is no assurance of success; failure to secure funding may force reductions or suspension of operations.